<DOC>
	<DOCNO>NCT00147316</DOCNO>
	<brief_summary>Based previous study compare Duteplase [ recombinant tissue plasminogen activator ( rt-PA ) similar alteplase ] dos , perform clinical trial 0.6mg/kg , low internationally approve dosage 0.9mg/kg , aim assess efficacy safety alteplase Japanese .</brief_summary>
	<brief_title>Japan Alteplase Clinical Trial ( J-ACT ) : Efficacy Safety Study Tissue Plasminogen Activator ( Alteplase ) Ischemic Stroke</brief_title>
	<detailed_description>Based previous study compare Duteplase ( rt-PA similar alteplase ) dose , perform clinical trial 0.6mg/kg , low internationally approve dosage 0.9mg/kg , aim assess efficacy safety alteplase Japanese . The primary endpoint rate patient mRS score 0-1 3 month incidence sICH within 36 hour . Thresholds endpoint determine calculate 90 % confidence interval weight average derive publish report . The protocol define accord National Institute Neurological Disorders Stroke ( NINDS ) rt-PA stroke study slight modification .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Brain Ischemia</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Patients acute ischemic stroke within 3 hour onset , clearly defined time onset 1. patient rapidly improve neurological symptom minor neurological deficit ( National Institutes Health Stroke Scale ( NIHSS ) score ≤4 ) prior start treatment 2 . Computed Tomography ( CT ) evidence nonminor early ischemic sign ( minor early ischemic sign define involvement onethird less middle cerebral artery area ) 3 . CT evidence cerebral hemorrhage subarachnoid hemorrhage 4. symptom suggestive subarachnoid hemorrhage 5. lactation , pregnancy suggestive pregnancy ; menstruation 6. platelet count 100,000/mm3 7. heparin administration within 48 hour precede stroke onset elevate activated partial thromboplastin time ( APTT ) ; current use oral anticoagulant International Normalized Ratio ( INR ) ≥1.7 ; use drug allow administer concomitantly alteplase ( thrombolytic agent , ozagrel sodium , argatroban edaravone ) prior study treatment 8. major surgery serious trauma within precede 14 day ; serious head spinal cord trauma within precede 3 month 9. history gastrointestinal urinary tract hemorrhage within previous 21 day 10. arterial puncture noncompressible site within precede 7 day 11. history stroke within precede 3 month ; history intracranial hemorrhage increase risk intracranial hemorrhage cerebral aneurysm , arteriovenous malformation , neoplasm , etc . 12. concurrent severe hepatic renal dysfunction 13. malignant tumor treatment 14. systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg 15. need aggressive treatment reduce blood pressure limit ( 14 ) ) 16. blood glucose level &lt; 50 mg/dL &gt; 400 mg/dL 17. acute myocardial infarction ( AMI ) endocarditis AMI 18. concurrent infectious endocarditis , moyamoya disease ( Willis circle occlusion syndrome ) , aortic dissection , neck trauma , etc . ; strong suspicion ischemic cerebrovascular disorder cause nonthrombotic occlusion hemodynamic condition 19. seizure onset stroke 20. coma ( Japan Coma Scale score ≥100 ) 21. mRS score ≥2 stroke onset 22. history hypersensitivity protein preparation 23. difficulty monitor 3 month 24. less 3 month since clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>acute stroke</keyword>
	<keyword>thrombolytic therapy</keyword>
	<keyword>tissue plasminogen activator</keyword>
</DOC>